佰金生命科學：2026年報.pdf

1、OVERVIEW概覽Corporate Information公司資料2Financial Highlights財務摘要4Management Discussion and Analysis管理層討論及分析5Profile of Directors董事履歷24Corporate Governance Report企業管治報告28Report of the Directors董事會報告44FINANCIAL SECTION財務部分Independent Auditors Report獨立核數師報告57Consolidated Statement of Profit or Loss綜合損益表64C

2、onsolidated Statement of Profit or Loss and Other Comprehensive Income綜合損益及其他 全面收益表65Consolidated Statement of Financial Position綜合財務狀況表66Consolidated Statement of Changes in Equity綜合權益變動表68Consolidated Statement of Cash Flows綜合現金流量表69Notes to the Consolidated Financial Statements綜合財務報表附註71Five Year

3、 Financial Summary五年財務摘要184Contents 目錄Baijin Life Science Holdings Limited 佰金生命科學控股有限公司2Corporate Information公司資料BOARD OF DIRECTORSExecutive DirectorsMr.Cheung Sze Ming Mr.Dong PengDr.Su YaoyaoNon-executive DirectorsMr.Zhu Yongjun Mr.Cheng Chi KinMs.Xie ChunchenIndependent Non-executive DirectorsMr.

4、Wong Siu Keung,Joe Mr.Chang ChunyuMs.Shen Ding(appointed on 2 March 2026)AUDIT COMMITTEEMr.Wong Siu Keung,Joe(Chairman)Mr.Chang ChunyuMs.Shen Ding(appointed on 2 March 2026)REMUNERATION COMMITTEEMr.Wong Siu Keung,Joe(Chairman)Mr.Cheung Sze Ming Mr.Zhu YongjunMr.Chang ChunyuDr.Su YaoyaoMs.Shen Ding(a

5、ppointed on 2 March 2026)NOMINATION COMMITTEEMr.Wong Siu Keung,Joe(Chairman)Mr.Cheung Sze Ming Mr.Zhu YongjunMr.Chang ChunyuDr.Su YaoyaoMs.Xie Chunchen(appointed on 30 June 2025)Ms.Shen Ding(appointed on 2 March 2026)COMPANY SECRETARYMr.Cheung Sze MingAUDITORBaker Tilly Hong Kong Limited(Registered

6、Public Interest Entity Auditor)LEGAL ADVISERSLo&LawyersConyers Dill&Pearman Fangda Partners董事會執行董事張詩敏先生董鵬先生蘇耀耀博士非執行董事朱勇軍先生鄭子堅先生謝春辰女士獨立非執行董事黃兆強先生常春雨先生沈定女士（於2026年3月2日獲委任）審核委員會黃兆強先生（主席）常春雨先生沈定女士（於2026年3月2日獲委任）薪酬委員會黃兆強先生（主席）張詩敏先生朱勇軍先生常春雨先生蘇耀耀博士沈定女士（於2026年3月2日獲委任）提名委員會黃兆強先生（主席）張詩敏先生朱勇軍先生常春雨先生蘇耀耀博士謝春辰女士（於